Who Owns AmerisourceBergen?

• Parent Company: Cencora Inc.
• Ownership Type: Brand division
• Company Type: Publicly Traded
• Stock Ticker: NYSE: COR

• Founded: 2001
• Founders: Formed through merger of AmeriSource and Bergen Brunswig

• Founded: 2001
• Headquarters: Conshohocken, Pennsylvania, USA
• Company Type: Publicly Traded
• Stock: NYSE: COR
• Revenue: approximately $293 billion (FY2024, year ended September 2024)
• Employees: Approximately 47,000

Visit Cencora Inc. website

• Headquarters: Conshohocken, Pennsylvania, USA
• Manufacturing / Operations: United States

AmerisourceBergen operates under Cencora's comprehensive corporate responsibility framework, focusing on sustainable supply chain operations, environmental stewardship, and ethical business practices in the pharmaceutical distribution industry. As a critical link in the healthcare supply chain, AmerisourceBergen's sustainability efforts emphasize responsible operations, environmental compliance, and community health initiatives.

Sustainable Supply Chain Operations: AmerisourceBergen has implemented comprehensive sustainability initiatives across its distribution network, including energy efficiency programs, renewable energy investments, and alternative fuel vehicle deployment. The company completed solar photovoltaic installations at distribution facilities in fiscal 2024 and continues to invest in energy optimization programs to reduce Scope 1 and 2 emissions. AmerisourceBergen's logistics operations focus on reducing environmental impact while maintaining the integrity and safety of pharmaceutical products throughout the distribution process.

Environmental Compliance and Green Operations: AmerisourceBergen maintains strict environmental compliance across all distribution facilities, implementing waste reduction programs, recycling initiatives, and sustainable packaging solutions. The company has invested in energy-efficient refrigeration systems, LED lighting upgrades, and water conservation measures across its distribution centers. AmerisourceBergen's environmental programs support Cencora's broader sustainability goals while ensuring compliance with pharmaceutical storage and transportation regulations.

Product Integrity and Patient Safety: AmerisourceBergen operates robust quality assurance and product integrity systems to ensure the safe and effective delivery of pharmaceutical products. The company implements temperature-controlled logistics, counterfeit prevention measures, and track-and-trace systems to maintain product quality throughout the supply chain. AmerisourceBergen's commitment to patient safety extends to proper handling, storage, and transportation of medications, supporting healthcare provider and patient needs.

Opioid Crisis Prevention and Responsibility: AmerisourceBergen has implemented comprehensive programs to address the opioid epidemic, including enhanced monitoring systems, prescriber education initiatives, and collaboration with healthcare providers on responsible opioid prescribing practices. The company was among the major distributors that agreed to pay $26 billion in 2022 to settle lawsuits related to opioid distribution practices, though the companies did not admit wrongdoing. AmerisourceBergen continues to implement preventive measures and monitoring systems to prevent diversion and misuse of controlled substances.

Ethical Business Practices and Compliance: AmerisourceBergen maintains comprehensive ethics and compliance programs across all operations, including anti-corruption measures, fair competition practices, and responsible marketing. The company's business conduct guidelines emphasize transparency, accountability, and ethical decision-making in all pharmaceutical distribution activities. AmerisourceBergen works closely with regulatory agencies including the FDA and DEA to ensure compliance with pharmaceutical distribution regulations and industry standards.

Community Health Initiatives: AmerisourceBergen supports community health programs through partnerships with healthcare organizations, patient advocacy groups, and public health initiatives. The company's community engagement focuses on improving access to medications, supporting healthcare education, and addressing public health challenges. AmerisourceBergen's corporate citizenship programs reflect its role as a critical healthcare infrastructure provider and its commitment to community wellbeing.

AmerisourceBergen has received recognition for its operational excellence, supply chain innovation, and corporate responsibility initiatives, establishing itself as a leader in pharmaceutical distribution and healthcare logistics.

Supply Chain Excellence Awards: AmerisourceBergen has been recognized by industry organizations for its innovative supply chain solutions, operational efficiency, and technology implementation in pharmaceutical distribution. The company's advanced logistics systems, temperature-controlled transportation, and inventory management technologies have received acknowledgment from healthcare supply chain organizations and logistics industry publications for improving pharmaceutical distribution efficiency and reliability.

Corporate Responsibility Recognition: AmerisourceBergen's sustainability and corporate responsibility programs have been acknowledged by ESG rating agencies and corporate responsibility organizations. The company's comprehensive approach to environmental sustainability, opioid crisis prevention, and community health initiatives has been recognized for addressing critical challenges in the pharmaceutical industry while maintaining operational excellence.

Operational Performance Awards: AmerisourceBergen has received multiple awards for operational performance, including distribution efficiency, inventory management, and customer service excellence. The company's ability to maintain high service levels while implementing sustainability initiatives and compliance programs has been acknowledged by healthcare industry organizations and customer satisfaction surveys.

Technology and Innovation Recognition: AmerisourceBergen's investment in distribution technology, automation systems, and digital transformation initiatives has received recognition from technology organizations and industry publications. The company's implementation of advanced tracking systems, inventory optimization algorithms, and digital platforms has been acknowledged for modernizing pharmaceutical distribution operations.

Workplace and Culture Awards: AmerisourceBergen has been recognized as an employer of choice in the pharmaceutical distribution industry, receiving awards for workplace culture, employee development programs, and diversity and inclusion initiatives. The company's commitment to employee training, safety programs, and career development has been acknowledged by human resources organizations and industry associations.

Healthcare Industry Leadership: AmerisourceBergen's role in supporting healthcare delivery and improving pharmaceutical access has been recognized by healthcare organizations and patient advocacy groups. The company's contributions to healthcare supply chain reliability, emergency response capabilities, and support for public health initiatives have been acknowledged for demonstrating corporate citizenship in the healthcare sector.

AmerisourceBergen has faced significant legal challenges and controversies related to the opioid epidemic, cybersecurity incidents, and regulatory compliance issues that have tested the company's reputation and business practices in the pharmaceutical distribution industry.

Opioid Epidemic Lawsuits and Settlement: AmerisourceBergen was among the major pharmaceutical distributors sued by multiple states for contributing to the opioid crisis through excessive distribution of opioid pain medications. In 2022, AmerisourceBergen, along with McKesson, Cardinal Health, and Johnson & Johnson, agreed to pay $26 billion to settle lawsuits with 46 states, Washington DC, and 90% of municipal governments. The settlement addressed allegations that the companies distributed excessive quantities of opioids without adequate monitoring systems, though the companies did not admit wrongdoing.

Cybersecurity Incident (2024): In May 2024, Cencora disclosed a cybersecurity incident that exposed patient information, raising concerns about data privacy and security in pharmaceutical distribution systems. The incident highlighted the vulnerabilities of healthcare supply chain digital systems and led to increased scrutiny of data protection practices across the pharmaceutical distribution industry. The company implemented enhanced security measures and worked with regulatory agencies to address the breach and protect patient information.

Regulatory Compliance Challenges: AmerisourceBergen has faced regulatory scrutiny from various agencies including the FDA, DEA, and state pharmacy boards regarding compliance with pharmaceutical distribution regulations, controlled substance handling requirements, and reporting obligations. The company has invested in enhanced compliance programs, monitoring systems, and employee training to address regulatory requirements and prevent violations.

Walgreens Boots Alliance Relationship: AmerisourceBergen's strategic relationship with Walgreens Boots Alliance, which involved significant ownership stakes and distribution agreements, has faced scrutiny regarding potential conflicts of interest and market concentration concerns. Walgreens Boots Alliance gradually reduced its ownership stake from approximately 30% in 2016 to below 5% by mid-2025, though the distribution partnership continues through 2029.

Market Concentration Concerns: As one of three major distributors controlling over 90% of the U.S. pharmaceutical wholesale market, AmerisourceBergen has faced scrutiny regarding market concentration and potential anti-competitive practices. Regulatory agencies and healthcare organizations have raised concerns about the impact of market consolidation on drug prices, access, and innovation in the pharmaceutical supply chain.

Product Quality and Safety Issues: AmerisourceBergen has occasionally faced challenges related to product quality, storage conditions, and transportation safety, particularly concerning temperature-sensitive pharmaceuticals and specialty medications. The company has implemented enhanced quality control systems, monitoring technologies, and employee training programs to address these issues and maintain product integrity throughout the distribution process.

Pricing and Business Practice Controversies: AmerisourceBergen has faced criticism regarding pricing practices, contract terms, and business relationships with pharmaceutical manufacturers and healthcare providers. Some healthcare organizations and patient advocacy groups have raised concerns about distribution costs, contract transparency, and the impact of distribution practices on drug prices and healthcare affordability.

AmerisourceBergen operates within Cencora's comprehensive corporate responsibility framework, focusing on sustainable pharmaceutical distribution, environmental stewardship, and ethical business practices as part of the company's commitment to creating healthier futures.

Environmental Sustainability Initiatives: Cencora has implemented comprehensive environmental programs across its distribution network, including solar photovoltaic installations completed in fiscal 2024 at key distribution facilities. The company focuses on reducing Scope 1 and 2 emissions through energy efficiency measures and renewable energy investments. Cencora's distribution centers incorporate energy optimization programs, waste reduction initiatives, and alternative fuel vehicles to minimize environmental impact while maintaining critical pharmaceutical supply chain operations.

Sustainable Supply Chain Management: AmerisourceBergen maintains responsible sourcing practices throughout its pharmaceutical distribution network, emphasizing environmental compliance and ethical supplier relationships. The company implements rigorous monitoring systems for temperature-sensitive pharmaceuticals and specialty medications, ensuring product integrity while reducing environmental footprint. Cencora's sustainability programs include closed-loop water recycling systems and renewable energy procurement at major distribution facilities, supporting the company's carbon neutrality goals.

Opioid Crisis Prevention and Responsibility: Following the $26 billion settlement in 2022, AmerisourceBergen has implemented enhanced monitoring systems and compliance programs to prevent excessive opioid distribution. The company has invested in advanced tracking systems, staff training programs, and partnerships with regulatory agencies to ensure responsible pharmaceutical distribution practices. These initiatives demonstrate the company's commitment to addressing public health crises while maintaining essential medicine access.

Community Health and Social Impact: Through the Cencora Impact Foundation (formerly AmerisourceBergen Foundation), the company supports community health initiatives and patient well-being programs. The foundation focuses on improving health outcomes through partnerships with healthcare organizations and community groups, particularly in underserved communities. AmerisourceBergen's community engagement programs include health education initiatives, patient access programs, and partnerships with healthcare providers to enhance medication access and adherence.

Diversity and Inclusion Leadership: In 2024, AmerisourceBerg appointed Ann Anaya as SVP and Chief Diversity Equity and Inclusion Officer, demonstrating the company's commitment to fostering a diverse and inclusive workplace. The company has implemented comprehensive diversity programs and initiatives to promote equity in pharmaceutical distribution operations, workforce representation, and supplier relationships.

Ethical Governance and Compliance: AmerisourceBergen maintains robust compliance programs for FDA, DEA, and state pharmacy board regulations, with enhanced monitoring systems for controlled substances and reporting requirements. The company has invested in comprehensive employee training programs, ethical sourcing standards, and regulatory compliance systems to ensure adherence to pharmaceutical distribution regulations and business ethics throughout its operations.